Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07639138CT.gov Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC | — | Recruiting | — | — | — |
NCT07618546CT.gov A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors | — | Not Yet Recruiting | — | — | — |
NCT07589244CT.gov A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC | — | Recruiting | — | — | — |
NCT07314372CT.gov FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07363356CT.gov Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer | — | Not Yet Recruiting | — | — | — |
NCT07351513CT.gov A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07324473CT.gov Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study | — | Not Yet Recruiting | — | — | — |
NCT07154082CT.gov Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07309419CT.gov A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07192848CT.gov Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy | — | Not Yet Recruiting | — | — | — |
Show 64 more trialsShow fewer
NCT07147101CT.gov Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment | — | Recruiting | — | — | — |
NCT05660213CT.gov A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer | — | Not Yet Recruiting | — | — | — |
NCT06893887CT.gov Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06796803CT.gov Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) | — | Not Yet Recruiting | — | — | — |
NCT07157969CT.gov ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | — | Recruiting | — | — | — |
NCT06538935CT.gov SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06546280CT.gov A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | — | Not Yet Recruiting | — | — | — |
NCT06485466CT.gov TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06454578CT.gov Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | — | Recruiting | — | — | — |
NCT06482008CT.gov HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study | — | Not Yet Recruiting | — | — | — |
NCT06349317CT.gov Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | — | Recruiting | — | — | — |
NCT06607107CT.gov mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria | — | Recruiting | — | — | — |
NCT06360042CT.gov Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | — | Recruiting | — | — | — |
NCT06172205CT.gov Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | — | Recruiting | — | — | — |
NCT05924997CT.gov Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05839197CT.gov A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC | — | Unknown | — | — | — |
NCT05613478CT.gov Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05760430CT.gov The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05367687CT.gov A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | — | Completed | — | — | — |
NCT05320692CT.gov A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05313282CT.gov A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | — | Unknown | — | — | — |
NCT05412589CT.gov mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC | — | Recruiting | — | — | — |
NCT05717738CT.gov Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05198609CT.gov Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | — | Active Not Recruiting | — | — | — |
NCT05550025CT.gov TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer | — | Unknown | — | — | — |
NCT04985136CT.gov A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT04930315CT.gov SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04724226CT.gov Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05062837CT.gov Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | — | Unknown | — | — | — |
NCT04850040CT.gov A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin | — | Unknown | — | — | — |
NCT04639180CT.gov A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | — | Active Not Recruiting | — | — | — |
NCT04521153CT.gov Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04826406CT.gov A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). | — | Unknown | — | — | — |
NCT04701060CT.gov Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04665362CT.gov IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | — | Unknown | — | — | — |
NCT05171309CT.gov Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC | — | Unknown | — | — | — |
NCT05535998CT.gov TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT | — | Completed | — | — | — |
NCT04559607CT.gov TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma | — | Unknown | — | — | — |
NCT04523662CT.gov Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | — | Unknown | — | — | — |
NCT04411706CT.gov A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05713994CT.gov Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04191889CT.gov A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | — | Unknown | — | — | — |
NCT04297202CT.gov SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04204577CT.gov The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | — | Unknown | — | — | — |
NCT04035876CT.gov Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | — | Unknown | — | — | — |
NCT03764293CT.gov A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC | — | Completed | — | — | — |
NCT04014101CT.gov SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03839550CT.gov Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | — | Unknown | — | — | — |
NCT03793725CT.gov A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC | — | Unknown | — | — | — |
NCT03722875CT.gov SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery | — | Unknown | — | — | — |
NCT03510416CT.gov Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03520257CT.gov The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus | — | Unknown | — | — | — |
NCT03511703CT.gov The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients | — | Unknown | — | — | — |
NCT03463876CT.gov A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) | — | Completed | — | — | — |
NCT03398122CT.gov Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03261791CT.gov Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection | — | Unknown | — | — | — |
NCT03278444CT.gov Treatment of Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03114085CT.gov Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03046979CT.gov Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) | — | Unknown | — | — | — |
NCT02942329CT.gov Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | — | Unknown | — | — | — |
NCT02702323CT.gov Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study | — | Unknown | — | — | — |
NCT02727309CT.gov A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients | — | Unknown | — | — | — |
NCT02329860CT.gov Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | — | Completed | — | — | — |
NCT01192971CT.gov A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivoceranib (this asset) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BB · 66 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Rivoceranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Cancer | — | P4 | BBB · 73 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 72 |
| Cancer | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivoceranib in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivoceranib-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →